What's in Mundipharma (China) Pharmaceutical Co. Ltd's pipeline?

Mundipharma (China) Pharmaceutical Co. Ltd has 6 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Mundipharma (China) Pharmaceutical Co. Ltd's portfolio?

Top competitors by shared drug class: University of California, San Francisco, BioDelivery Sciences International, Purdue Pharma LP, Ajay Wasan, MD, Msc, Asbjørn Mohr Drewes.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mundipharma-china-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Mundipharma (China) Pharmaceutical Co. Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mundipharma (China) Pharmaceutical Co. Ltd pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
OXYCONTIN®	OXYCONTIN®	marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor	Pain
Buprenorphine transdermal patches	Buprenorphine transdermal patches	phase 3	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)	Pain Management / Addiction Medicine
OxyNorm Capsules	OxyNorm Capsules	phase 3	Opioid analgesic	Mu-opioid receptor (OPRM1)	Pain Management
Morphine Sulfate Sustained-Release Tablet	Morphine Sulfate Sustained-Release Tablet	phase 3	Opioid	mu-opioid receptor	Pain Management

Therapeutic area mix

Pain Management · 2
Pain · 1
Pain Management / Addiction Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University of California, San Francisco · 3 shared drug classes
BioDelivery Sciences International · 2 shared drug classes
Purdue Pharma LP · 2 shared drug classes
Ajay Wasan, MD, Msc · 1 shared drug class
Asbjørn Mohr Drewes · 1 shared drug class
Archimedes Development Ltd · 1 shared drug class
Boston Children's Hospital · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mundipharma (China) Pharmaceutical Co. Ltd:

Cite this brief

Drug Landscape (2026). Mundipharma (China) Pharmaceutical Co. Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mundipharma-china-pharmaceutical-co-ltd. Accessed 2026-05-18.